Role of Nutrition in Inflammatory Bowel Disease (IBD): New Therapeutic Approaches and Recent Outcomes

Authors

  • Nallely Bueno Hernández Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, D.F., México
  • Josep MañeAlmero Gastroenterology & Nutrition Research Unit, Health Sciences Research Institute, Germans Trias I Pujol Foundation, Badalona, Barcelona, Catalonia, and CIBERehd, Barcelona, Catalonia, Spain
  • Isabel Cortes Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, D.F., México
  • Jesús Yamamoto-Furusho Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, D.F., México

DOI:

https://doi.org/10.6000/1929-5634.2012.01.02.4

Keywords:

Inflammatory Bowel Disease, Nutrients, Fatty Acids and Treatment

Abstract

Inflammatory bowel disease (IBD) is the generic term given to a heterogeneous group of disorders of the gastrointestinal tract that are characterized by chronic inflammation. The major forms of IBD are Crohn’s disease (CD) and ulcerative colitis (UC), which are increasing in incidence, prevalence and severity in many countries; these are characterized by intestinal inflammation and are believed to involve complex interactions between genetic, immunological and environmental factors. The incidence continues to rise, both in low and in high-incidence areas. Several dietary regimes may modify disease symptoms, in part through their actions on the host microbe. However, other dietary factors could affect the microbiotic or genetic expression in IBD patients in different ways. The purpose of this review is to discuss the most recent evidence from the literature on the use of nutritional therapy in the treatment of IBD and to review the role of environmental factors on the progressive increase of prevalence. The epidemiological data reveal an increasing incidence of IBD in recent years, which may be the result of increased intake of simple sugars and consumption disproportionate of fat (saturated and unsaturated). Intestinal permeability and inflammation could improve with proper diet in protein, probiotics and FA (n-3 and n-6). Diet and the host microbiota are likely to play important but as yet poorly defined roles therefore, is necessary to continue investigating to implement molecular findings in clinical treatments or adjunctive therapies.

References

Podolsky DK. Inflammatory Bowel Disease. N Engl J Med 2002; 347: 417-29. http://dx.doi.org/10.1056/NEJMra020831

Yamamoto-Furusho JK. Clinical epidemiology of ulcerative colitis in Mexico: a single hospital-based study in a 20-year period (1987-2006). J Clin Gastroenterol 2009; 43: 221-24. http://dx.doi.org/10.1097/MCG.0b013e31817a76b4

Nell S, Suerbaum S, Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol 2010; 8: 564-77. http://dx.doi.org/10.1038/nrmicro2403

Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-17. http://dx.doi.org/10.1038/nature10209

Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med 2012; 1: 17-27.

Semrad CV. Use of Parenteral nutrition in patients with Inflammatory Bowel Disease. Gastroenterol Hepatol 2012; 8: 393-5.

Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D’Haens G, et al. IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the world digestive health day 2010- Inflammatory Bowel Disease Task Force Meeting. Inflamm Bowel Dis 2011; 17: 639-44. http://dx.doi.org/10.1002/ibd.21409

Loftus CG, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007; 13: 254-61. http://dx.doi.org/10.1002/ibd.20029

Lovasz BD, Golovics PA, Vegh Z, Lakatos PL. New trends in inflammatory bowel disease epidemiology and disease course in. Digest Liver Dis 2012: pii: S1590-8658(12)00328-3. doi: 10.1016/j.dld.2012.08.020. [Epub ahead of print]. http://dx.doi.org/10.1016/j.dld.2012.08.020

Kappelman MD, Moore KR, Allen JF, Cook SF. Recent trends in the prevalence of Crohn’s Disease and Ulcerative Colitis in a commercially insured US population. Dig Dis Sci 2012; doi: 10.1007/s10620-012-2371-5 [Epub ahead of print]. http://dx.doi.org/10.1007/s10620-012-2371-5

Song OW, Wang Y, Chung CE, Song Bonita, Lee W. Is obesity development associated with dietary sugar intake in the U.S.? Nutrition 2012; 1-5.

Jakobsen C, Paerregaard A, Munkholm P, Wewer V. Environmental factors and risk of developing paediatric inflammatory bowel disease - A population based study 2007-2009. J Crohns Colitis 2012; [Epub ahead of print]. http://dx.doi.org/10.1016/j.crohns.2012.05.024

Knoch B, Barnett MP, Zhu S, Park ZA, Nones K, Dommels YE, et al. Genomewide analysis of dietary eicosapentaenoic acid and oleic acidinduced modulation of colon inflammation in interleukin-10 gene-deficient mice. J Nutrigenet Nutrigenomics 2009; 2: 9-28. http://dx.doi.org/10.1159/000134292

Molnár K, Vannay A, Szebeni B, Bánki NF, Sziksz E, Cseh A, et al. Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease. World J Gastroenterol 2012; 18: 3254-9.

Schicho R, Shaykhutdinov R, Ngo J, Nazyrova A, Schneider C, et al. Panaccione R. Quantitative metabolomic profiling of serum, plasma, and urine by 1H NMR spectroscopy discriminates between patients with Inflammatory Bowel Disease and healthy individuals. J Proteome Res 2012; 11: 3344−57. http://dx.doi.org/10.1021/pr300139q

Koleva PT, Valcheva RS, Sun X, Gänzle MG, Dieleman LA. Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats. Br J Nutr 2012; 16: 1-11.

Guarner F. Prebiotics in inflammatory bowel diseases. Br J Nutr 2007; 1: S85-9.

Walkera AW, Lawleyb TD. Therapeutic modulation of intestinal dysbiosis, Pharmacol Res 2012; pii: S1043-6618(12)00183-1. doi: 10.1016/j.phrs.2012.09.008. [Epub ahead of print]. http://dx.doi.org/10.1016/j.phrs.2012.09.008

Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-80. http://dx.doi.org/10.1038/nature09944

Jonkers D, Penders J, Masclee A, Pierik M, et al. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 2012; 72: 803-23. http://dx.doi.org/10.2165/11632710-000000000-00000

Mañé J, Lorén V, Pedrosa E, Ojanguren I, Xaus J, Cabré E et al. Lactobacillus fermentum CECT 5716 prevents and reverts intestinal damage on TNBS-induced colitis in mice. Inflamm Bowel Dis 2009; 15: 1155-63. http://dx.doi.org/10.1002/ibd.20908

Zakostelska Z, Kverka M, Klimesova K, Rossmann P, Mrazek J, et al. Kopecny J. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS ONE 2011; 6(11): e27961. http://dx.doi.org/10.1371/journal.pone.0027961

Xue H, Sufit AJD, Wischmeyer PE. Glutamine therapy improves outcome of in vitro and in vivo experimental colitis models. J Parenter Enteral Nutr 2011; 35: 188-97. http://dx.doi.org/10.1177/0148607110381407

Benjamin J, Makharia G, Ahuja V, Anand KD, Kalaivani M, Datta S, et al. Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn’s Disease: a randomized controlled trial. Dig Dis Sci 2012; 57: 1000-12. http://dx.doi.org/10.1007/s10620-011-1947-9

Cabré E, Domènech E. Impact of environmental and dietary factors on the course of inflammatory bowel disease. World J Gastroenterol 2012; 18: 3814-22. http://dx.doi.org/10.3748/wjg.v18.i29.3814

Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn‘s disease. Cochrane Database Syst Rev 2007; 24(1): CD000542.

Williams HRT, Willsmore JD, Cox J, Walker DG, Cobbold JFL, Taylor-Robinson SD, Orchard TR. Serum metabolic profiling in Inflammatory Bowel Disease. Dig Dis Sci 2012; 57: 2157-65. http://dx.doi.org/10.1007/s10620-012-2127-2

Sánchez-Fidalgo S, Villegas I, Cárdeno A, Talero E, Sánchez-Hidalgo M, Motilva V et al. Extra-virgin olive oil-enriched diet modulates DSS-colitis-associated colon carcinogenesis in mice. Clin Nutr 2010; 29: 663-73. http://dx.doi.org/10.1016/j.clnu.2010.03.003

Borniquela S, Janssona EA, Coleb MP, Freemanb BA, Lundberga JO. Nitrated oleic acid up-regulates PPARγ and attenuates experimental inflammatory bowel disease. Free Radic Biol Med 2010; 48: 499-505. http://dx.doi.org/10.1016/j.freeradbiomed.2009.11.014

Wisely BG, Miller BA, Davis GR, Thornquest DA, Johonson R, Spitzer T, et al. Hepatocyte nuclear factor 4 is a transcription factor the constitutively binds fatty acids. Structure 2002; 10: 1225-34. http://dx.doi.org/10.1016/S0969-2126(02)00829-8

Bueno-Hernández N, Sánchez-Muñoz F, Barreto-Zuñiga R, Dominguez-López A, Yamamoto-Furusho JK. Expression of HNF4g is downregulated in patients with active Ulcerative Colitis (UC) compared to UC patients in remission and healthy controls. Inflamm Bowel Dis 2011; 8: E91. http://dx.doi.org/10.1002/ibd.21753

Kaser A, Zeissig S, Blumberg RS. Inflammatory Bowel Disease. Annu Rev Immunol 2010; 28: 573-621. http://dx.doi.org/10.1146/annurev-immunol-030409-101225

Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc 2002; 61: 345-58. http://dx.doi.org/10.1079/PNS2002166

Ramakers JD, Mensink RP, Schaart G, Plat J. Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells. Lipids 2007; 42: 687-98. http://dx.doi.org/10.1007/s11745-007-3071-3

Cooney JM, Barnett MPG, Brewster D, Knoch B, McNabb WC, Laing WA, Roy NC. Proteomic analysis of colon tissue from Interleukin-10 gene-deficient mice fed polyunsaturated fatty acids with comparison to transcriptomic analysis. J Proteome Res 2012; 11: 1065-77. http://dx.doi.org/10.1021/pr200807p

Mañé J, Pedrosa E, Lorén V, Ojanguren I, Fluvia L, Cabré E, et al. Partial replacement of dietary (n-6) fatty acids with medium-chain triglycerides decreases the incidence of spontaneous colitis in Interleukin-10-deficient Mice. J Nutr 2009; 139: 603-10. http://dx.doi.org/10.3945/jn.108.101170

Mbodjia K, Charpentiera C, Guérina C, Quereca C, Bole-Feysota C, Azizc M. Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-κB in rats with TNBS-induced colitis. J Nutr Biochem 2012; [Epub ahead of print].

James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71: 343S-8S.

Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 2006; 103; 11276-81. http://dx.doi.org/10.1073/pnas.0601280103

Downloads

Published

2013-01-04

How to Cite

Hernández, N. B., MañeAlmero, J., Cortes, I., & Yamamoto-Furusho, J. (2013). Role of Nutrition in Inflammatory Bowel Disease (IBD): New Therapeutic Approaches and Recent Outcomes. Journal of Nutritional Therapeutics, 1(2), 132–137. https://doi.org/10.6000/1929-5634.2012.01.02.4

Issue

Section

Articles